Epidemiology of Hepatitis C Virus: People Who Inject Drugs and Other Key Populations

[1]  B. Hoen,et al.  Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV , 2018, AIDS.

[2]  S. Mauss,et al.  Direct‐acting antiviral treatment of chronic HCV‐infected patients on opioid substitution therapy: Still a concern in clinical practice? , 2018, Addiction.

[3]  C. Boucher,et al.  Declining Hepatitis C Virus (HCV) Incidence in Dutch Human Immunodeficiency Virus-Positive Men Who Have Sex With Men After Unrestricted Access to HCV Therapy , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  C. Latkin,et al.  Understanding and addressing hepatitis C reinfection in the oral direct‐acting antiviral era , 2018, Journal of viral hepatitis.

[5]  B. Lindenbach,et al.  Recovery of Infectious Hepatitis C Virus From Injection Paraphernalia: Implications for Prevention Programs Serving People Who Inject Drugs , 2018, The Journal of infectious diseases.

[6]  I. Veldhuijzen,et al.  Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: a focus on migrants from anti-HCV endemic countries , 2018, BMC Infectious Diseases.

[7]  D. Holtzman,et al.  Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014 , 2018, American journal of public health.

[8]  N. Hill,et al.  Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review , 2017, BMC Infectious Diseases.

[9]  P. Krajči,et al.  Are we ready to treat hepatitis C virus in individuals with opioid use disorder: assessment of readiness in European countries on the basis of an expert-generated model , 2017, European journal of gastroenterology & hepatology.

[10]  J. Leung,et al.  Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review , 2017, The Lancet. Global health.

[11]  J. Leung,et al.  Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review , 2017, The Lancet. Global health.

[12]  A. Hogewoning,et al.  Men who have sex with men starting pre-exposure prophylaxis (PrEP) are at risk of HCV infection: evidence from the Amsterdam PrEP study. , 2017, AIDS.

[13]  G. Dore,et al.  HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs , 2017, Current HIV/AIDS Reports.

[14]  D. Nelson,et al.  Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. , 2017, Annals of internal medicine.

[15]  V. Martel-Laferrière,et al.  Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIV , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  H. Stellbrink,et al.  HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. , 2017, Journal of hepatology.

[17]  H. El‐Serag,et al.  Global epidemiology and burden of HCV infection and HCV-related disease , 2017, Nature Reviews Gastroenterology &Hepatology.

[18]  S. Little,et al.  Can research at the end of life be a useful tool to advance HIV cure? , 2017, AIDS.

[19]  R. Chou,et al.  Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses. , 2016, The Lancet. Infectious diseases.

[20]  P. Mateu-Gelabert,et al.  Inactivation of HCV and HIV by microwave: a novel approach for prevention of virus transmission among people who inject drugs , 2016, Scientific Reports.

[21]  A. Petruzziello,et al.  Hepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in Europe , 2016, Infectious Agents and Cancer.

[22]  J. Macías,et al.  HCV epidemiology in high-risk groups and the risk of reinfection. , 2016, Journal of hepatology.

[23]  Reza Assadi,et al.  The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013 , 2016, The Lancet.

[24]  J. Cairns,et al.  Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation , 2016, Journal of hepatology.

[25]  P. Easterbrook,et al.  Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. , 2016, The Lancet. Infectious diseases.

[26]  P. Vickerman,et al.  Is increased hepatitis C virus case‐finding combined with current or 8‐week to 12‐week direct‐acting antiviral therapy cost‐effective in UK prisons? A prevention benefit analysis , 2016, Hepatology.

[27]  D. De Angelis,et al.  New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England , 2016, Journal of viral hepatitis.

[28]  C. Sabin,et al.  Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  H. Thiede,et al.  Reduction in Needle Sharing Among Seattle-Area Injection Drug Users Across 4 Surveys, 1994-2013. , 2016, American journal of public health.

[30]  R. Riley,et al.  Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  D. Y. Kim,et al.  The present and future disease burden of hepatitis C virus infections with today's treatment paradigm – volume 3 , 2015, Journal of viral hepatitis.

[32]  Lorie A. Kloda,et al.  The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis , 2015, PloS one.

[33]  S. Bird,et al.  Corrigendum to “National record linkage study of mortality for a large cohort of opioid users ascertained by drug treatment or criminal justice sources in England, 2005–2009” [Drug Alcohol Depend. 146 (2015) 17–23] , 2015, Drug and alcohol dependence.

[34]  Todd M. Allen,et al.  Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection--the InC3 Study. , 2015, The Journal of infectious diseases.

[35]  A. Mocroft,et al.  Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected? , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[36]  H. Hagan,et al.  Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men , 2015, AIDS.

[37]  H. Hagan,et al.  Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis. , 2015, The International journal on drug policy.

[38]  G. Dore,et al.  The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention , 2015, Current opinion in HIV and AIDS.

[39]  G. Dore,et al.  Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States , 2015, Annals of Internal Medicine.

[40]  C. Katlama,et al.  Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. , 2015, The lancet. HIV.

[41]  Q. Gong,et al.  Prediction of virological response by pretreatment hepatitis B virus reverse transcriptase quasispecies heterogeneity: the advantage of using next-generation sequencing. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[42]  P. Klenerman,et al.  Current knowledge and future perspectives on acute hepatitis C infection. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[43]  C. Sabin,et al.  P1289 : Understanding and preventing the HCV epidemic among men who have sex with men in the UK: A mathematical modelling analysis , 2015 .

[44]  T. Pilot‐Matias,et al.  Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. , 2015, JAMA.

[45]  K. Reddy,et al.  Distinct Features in Natural History and Outcomes of Acute Hepatitis C , 2015, Journal of clinical gastroenterology.

[46]  S. Bird,et al.  National record linkage study of mortality for a large cohort of opioid users ascertained by drug treatment or criminal justice sources in England, 2005–2009 , 2015, Drug and alcohol dependence.

[47]  K. Metzner,et al.  Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013 , 2015, Open forum infectious diseases.

[48]  M. Leshno,et al.  The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm – volume 2 , 2015, Journal of viral hepatitis.

[49]  H. Innes,et al.  Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most? , 2014, Gut.

[50]  H. Razavi,et al.  Global epidemiology and genotype distribution of the hepatitis C virus infection. , 2014, Journal of hepatology.

[51]  D. De Angelis,et al.  HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact , 2014, Journal of viral hepatitis.

[52]  Joan Colom I Farran,et al.  A policy-maker’s perspective on ‘ECDC and EMCDDA guidance: prevention and control of infectious diseases among people who inject drugs’ , 2014, BMC Infectious Diseases.

[53]  J. Lazarus,et al.  A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region , 2014, BMC Infectious Diseases.

[54]  M. Alavi,et al.  Continued low uptake of treatment for hepatitis C virus infection in a large community‐based cohort of inner city residents , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[55]  Ross J. Harris,et al.  Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios. , 2014, Journal of hepatology.

[56]  R. Geskus,et al.  Stabilizing Incidence of Hepatitis C Virus Infection Among Men Who Have Sex With Men in Amsterdam , 2014, Journal of acquired immune deficiency syndromes.

[57]  V. Hope,et al.  Factors associated with recently acquired hepatitis C virus infection in people who inject drugs in England, Wales and Northern Ireland: new findings from an unlinked anonymous monitoring survey , 2014, Epidemiology and Infection.

[58]  S. Hutchinson,et al.  Rapid Decline in HCV Incidence among People Who Inject Drugs Associated with National Scale-Up in Coverage of a Combination of Harm Reduction Interventions , 2014, PloS one.

[59]  Janet J. Hamilton,et al.  Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[60]  J. Lazarus,et al.  Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention , 2014, PloS one.

[61]  D. D. Des Jarlais,et al.  Self-reported testing, HIV status and associated risk behaviours among people who inject drugs in Europe: important differences between East and West , 2014, AIDS.

[62]  H. Stellbrink,et al.  Multiple hepatitis C virus (HCV) reinfections in HIV‐positive men who have sex with men: no influence of HCV genotype switch or interleukin‐28B genotype on spontaneous clearance , 2014, HIV medicine.

[63]  H. El‐Serag,et al.  HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV , 2014, Hepatology.

[64]  Heino Stöver,et al.  SMOKE IT! Promoting a change of opiate consumption pattern - from injecting to inhaling , 2014, Harm Reduction Journal.

[65]  G. Esmat,et al.  The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm , 2014, Journal of viral hepatitis.

[66]  M. Buti,et al.  Historical epidemiology of hepatitis C virus (HCV) in selected countries , 2014, Journal of viral hepatitis.

[67]  G. Dore,et al.  Can hepatitis C virus infection be eradicated in people who inject drugs? , 2014, Antiviral research.

[68]  H. Wand,et al.  Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999–2011 , 2014, Journal of viral hepatitis.

[69]  S. Oka,et al.  Incidence and Risk Factors for Incident Hepatitis C Infection Among Men Who Have Sex With Men With HIV-1 Infection in a Large Urban HIV Clinic in Tokyo , 2014, Journal of acquired immune deficiency syndromes.

[70]  M. Thursz,et al.  Hepatitis C, A Global Issue: Access to Care and New Therapeutic and Preventive Approaches in Resource-Constrained Areas , 2014, Seminars in Liver Disease.

[71]  M. Hellard,et al.  Eradication of hepatitis C infection: The importance of targeting people who inject drugs , 2013, Hepatology.

[72]  C. Rice,et al.  Expanded Classification of Hepatitis C Virus Into 7 Genotypes and 67 Subtypes: Updated Criteria and Genotype Assignment Web Resource , 2013, Hepatology.

[73]  R. Schinazi,et al.  Treatment as prevention and cure towards global eradication of hepatitis C virus. , 2013, Trends in microbiology.

[74]  P. Bruggmann.  Treatment as prevention: The breaking of taboos is required in the fight against hepatitis C among people who inject drugs , 2013, Hepatology.

[75]  B. Gazzard,et al.  Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM , 2013, AIDS.

[76]  J. Rich,et al.  Incidence and prevalence of hepatitis C in prisons and other closed settings: Results of a systematic review and meta‐analysis , 2013, Hepatology.

[77]  S. Lenton,et al.  The relationship between age and risky injecting behaviours among a sample of Australian people who inject drugs. , 2013, Drug and alcohol dependence.

[78]  G. Dore,et al.  Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[79]  G. Dore,et al.  Epidemiology and natural history of HCV infection , 2013, Nature Reviews Gastroenterology &Hepatology.

[80]  Tara S. Beattie,et al.  Is the HCV-HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission? , 2013, Drug and alcohol dependence.

[81]  M. Hellard,et al.  Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals , 2013, Hepatology.

[82]  M. Hellard,et al.  Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[83]  P. Vickerman,et al.  Combination Interventions to Prevent HCV Transmission Among People Who Inject Drugs: Modeling the Impact of Antiviral Treatment, Needle and Syringe Programs, and Opiate Substitution Therapy , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[84]  A. de Gottardi,et al.  Recommendations for the management of hepatitis C virus infection among people who inject drugs. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[85]  R. Detels,et al.  Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984-2011. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[86]  V. Hope,et al.  Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association , 2013, Epidemiology and Infection.

[87]  W. Miller,et al.  Community viral load as a measure for assessment of HIV treatment as prevention. , 2013, The Lancet. Infectious diseases.

[88]  M. Salminen,et al.  Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening , 2013, BMC Infectious Diseases.

[89]  D. D. Des Jarlais,et al.  Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[90]  H. Innes,et al.  Review and meta-analysis of the association between self-reported sharing of needles/syringes and hepatitis C virus prevalence and incidence among people who inject drugs in Europe. , 2013, The International journal on drug policy.

[91]  M. Danta,et al.  Sexually transmitted hepatitis C infection: the new epidemic in MSM? , 2012, Current opinion in infectious diseases.

[92]  P. Bruggmann.  Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers , 2012, Journal of viral hepatitis.

[93]  C. Lewden,et al.  All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection. , 2012, Journal of hepatology.

[94]  F. Serre,et al.  Change in HIV-HCV Risk-Taking Behavior and Seroprevalence Among Opiate Users Seeking Treatment Over an 11-year Period and Harm Reduction Policy , 2012, AIDS and Behavior.

[95]  H. Günthard,et al.  Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[96]  G. Lauer,et al.  Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. , 2012, The Lancet. Infectious diseases.

[97]  M. Kretzschmar,et al.  The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam. , 2012, Addiction.

[98]  R. Monina Klevens,et al.  The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007 , 2012, Annals of Internal Medicine.

[99]  P. Vickerman,et al.  Cost‐effectiveness of hepatitis C virus antiviral treatment for injection drug user populations , 2012, Hepatology.

[100]  H. Hagan.  Agent, host, and environment: hepatitis C virus in people who inject drugs. , 2011, The Journal of infectious diseases.

[101]  S. Ciesek,et al.  Inactivation and survival of hepatitis C virus on inanimate surfaces. , 2011, The Journal of infectious diseases.

[102]  Jean-Louis Bara,et al.  Hepatitis C transmission in injection drug users: could swabs be the main culprit? , 2011, The Journal of infectious diseases.

[103]  M. J. van de Laar,et al.  Trends in HIV and hepatitis C virus infections among injecting drug users in Europe, 2005 to 2010. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[104]  J. V. D. van der Meer,et al.  Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM , 2011, AIDS.

[105]  J. Parry,et al.  The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. , 2011, Addiction.

[106]  J. Grebely,et al.  Management of HCV and HIV infections among people who inject drugs. , 2011, Current opinion in HIV and AIDS.

[107]  B. Grady,et al.  No impact of hepatitis C virus infection on mortality among drug users during the first decade after seroconversion. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[108]  M. Buti,et al.  The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference * , 2011, Journal of viral hepatitis.

[109]  Louisa Degenhardt,et al.  Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews , 2011, The Lancet.

[110]  P. Vickerman,et al.  Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. , 2011, Journal of hepatology.

[111]  J. Parry,et al.  Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots , 2011, Journal of viral hepatitis.

[112]  M. Vogel,et al.  Trouble with Bleeding: Risk Factors for Acute Hepatitis C among HIV-Positive Gay Men from Germany—A Case-Control Study , 2011, PloS one.

[113]  R. Barth,et al.  Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. , 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[114]  David L. Thomas,et al.  Curing hepatitis C with pills: a step toward global control , 2010, The Lancet.

[115]  M. Abdel-hamid,et al.  HCV iatrogenic and intrafamilial transmission in Greater Cairo, Egypt , 2010, Gut.

[116]  B. Lindenbach,et al.  Survival of hepatitis C virus in syringes: implication for transmission among injection drug users. , 2010, The Journal of infectious diseases.

[117]  M. Danta,et al.  Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. , 2010, AIDS.

[118]  H. Krarup,et al.  Mortality in HIV‐infected injection drug users with active vs cleared hepatitis C virus‐infection: a population‐based cohort study , 2010, Journal of viral hepatitis.

[119]  H. Hagan,et al.  Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. , 2010, The Journal of infectious diseases.

[120]  J. Kaldor,et al.  Incidence and risk for acute hepatitis C infection during imprisonment in Australia , 2010, European Journal of Epidemiology.

[121]  Kelly P Burke,et al.  Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence , 2010, Immunologic research.

[122]  Judy Gold,et al.  Hepatitis C treatment for injection drug users: a review of the available evidence. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[123]  I. Stolte,et al.  Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic , 2009, AIDS.

[124]  E. Oppenheimer,et al.  A situation update on HIV epidemics among people who inject drugs and national responses in South-East Asia Region. , 2009, AIDS.

[125]  Martin Fisher,et al.  Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. , 2009, Gastroenterology.

[126]  J. Raffa,et al.  Low uptake of treatment for hepatitis C virus infection in a large community‐based study of inner city residents , 2009, Journal of viral hepatitis.

[127]  Evan Wood,et al.  Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study , 2009, BMJ : British Medical Journal.

[128]  U. Siebert,et al.  HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality , 2009, BMC public health.

[129]  J. Parry,et al.  Prevalence and incidence of hepatitis C in injecting drug users attending genitourinary medicine clinics , 2008, Epidemiology and Infection.

[130]  J. Parry,et al.  Diagnosis of acute hepatitis C virus infection and estimated incidence in low‐ and high‐risk English populations , 2008, Journal of viral hepatitis.

[131]  Matthew Hickman,et al.  Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review , 2008, The Lancet.

[132]  M. Simm,et al.  Intranasal transmission of hepatitis C virus: virological and clinical evidence. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[133]  A. Branch,et al.  Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. , 2008, The Journal of infectious diseases.

[134]  N. Hunt,et al.  Distributing foil from needle and syringe programmes (NSPs) to promote transitions from heroin injecting to chasing: An evaluation , 2008, Harm reduction journal.

[135]  D. Vlahov,et al.  Limited Uptake of Hepatitis C Treatment Among Injection Drug Users , 2008, Journal of Community Health.

[136]  M. Salminen,et al.  European monitoring of notifications of hepatitis C virus infection in the general population and among injecting drug users (IDUs) - the need to improve quality and comparability. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[137]  Sanaa M Kamal,et al.  Hepatitis C genotype 4: What we know and what we don't yet know , 2008, Hepatology.

[138]  D. Hedrich,et al.  From margin to mainstream: The evolution of harm reduction responses to problem drug use in Europe , 2008 .

[139]  A. Charlett,et al.  Increase in diagnosed newly acquired hepatitis C in HIV-positive men who have sex with men across London and Brighton, 2002–2006: is this an outbreak? , 2007, Sexually Transmitted Infections.

[140]  J. Kaldor,et al.  Further evidence of HCV sexual transmission among HIV-positive men who have sex with men: response to Danta et al. , 2007, AIDS.

[141]  T. Rhodes,et al.  Global estimates of prevalence of HCV infection among injecting drug users. , 2007, The International journal on drug policy.

[142]  R. Coutinho,et al.  Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users , 2007, Addiction.

[143]  P. Pradat,et al.  Epidemiological characteristics and medical follow-up of 61 patients with acute hepatitis C identified through the hepatitis C surveillance system in France , 2007, Epidemiology and Infection.

[144]  J. V. D. van der Meer,et al.  Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. , 2007, The Journal of infectious diseases.

[145]  J. Kaldor,et al.  High incidence of hepatitis C virus reinfection within a cohort of injecting drug users , 2007, Journal of viral hepatitis.

[146]  Anne M Johnson,et al.  Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours , 2007, AIDS.

[147]  Richard D Moore,et al.  Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic , 2006, AIDS.

[148]  B. Bell,et al.  The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. , 2006, Journal of hepatology.

[149]  M. Prins,et al.  Decline in HIV incidence and injecting, but not in sexual risk behaviour, seen in drug users in Amsterdam: a 19-year prospective cohort study , 2006, AIDS.

[150]  C. Rouzioux,et al.  Increase in hepatitis C virus incidence in HIV-1-infected patients followed up since primary infection , 2006, Sexually Transmitted Infections.

[151]  J. Desenclos,et al.  Les modes de transmission du virus de l’hépatite C : approches méthodologiques , 2006 .

[152]  C. Rouzioux,et al.  Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy , 2006, AIDS.

[153]  J. Kaldor,et al.  Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies , 2006, Journal of viral hepatitis.

[154]  S. Bird,et al.  Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland , 2005, Hepatology.

[155]  Colin W Shepard,et al.  Global epidemiology of hepatitis C virus infection. , 2005, The Lancet. Infectious diseases.

[156]  H. Thio,et al.  A cluster of acute hepatitis C virus infection among men who have sex with men – results from contact tracing and public health implications , 2005, AIDS.

[157]  L. Gambotti,et al.  Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001-2004. , 2005, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[158]  R. Garfein,et al.  Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[159]  O. Dalgard.  Follow-up studies of treatment for hepatitis C virus infection among injection drug users. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[160]  P. Simmonds,et al.  Genetic diversity and evolution of hepatitis C virus--15 years on. , 2004, The Journal of general virology.

[161]  Y. Gilleece,et al.  Increased numbers of acute hepatitis C infections in HIV positive homosexual men; is sexual transmission feeding the increase? , 2004, Sexually Transmitted Infections.

[162]  J. Tang,et al.  Failure to diagnose recent hepatitis C virus infections in London injecting drug users , 2004, Journal of medical virology.

[163]  O. Adeyemi,et al.  Hepatitis C treatment eligibility in an urban population with and without HIV coinfection. , 2004, AIDS patient care and STDs.

[164]  Y. Hutin,et al.  The global burden of disease attributable to contaminated injections given in health care settings , 2004, International journal of STD & AIDS.

[165]  H. Hagan,et al.  Does bleach disinfection of syringes help prevent hepatitis C virus transmission? , 2003, Epidemiology.

[166]  M. Busch,et al.  Hepatitis C virus seroconversion among young injection drug users: relationships and risks. , 2002, The Journal of infectious diseases.

[167]  B. Edlin.  Prevention and treatment of hepatitis C in injection drug users , 2002, Hepatology.

[168]  J. Desenclos,et al.  Outbreak of Hepatitis C Virus Infection in a Hemodialysis Unit: Potential Transmission by the Hemodialysis Machine? , 2002, Infection Control & Hospital Epidemiology.

[169]  E. Drucker,et al.  Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. , 2002, The Lancet. Infectious diseases.

[170]  M. Memon,et al.  Hepatitis C: an epidemiological review , 2002, Journal of viral hepatitis.

[171]  P. Lopalco,et al.  Risk of parenterally transmitted hepatitis following exposure to surgery or other invasive procedures: results from the hepatitis surveillance system in Italy. , 2001, Journal of hepatology.

[172]  J. Stephenson.  Former addicts face barriers to treatment for HCV. , 2001, JAMA.

[173]  M. McFarlane,et al.  The Internet as a newly emerging risk environment for sexually transmitted diseases. , 2000, JAMA.

[174]  B. Edlin,et al.  The effect of syringe exchange use on high-risk injection drug users: a cohort study , 2000, AIDS.

[175]  L. Hoffer,et al.  HIV-1 transmission in injection paraphernalia: heating drug solutions may inactivate HIV-1. , 1999, Journal of acquired immune deficiency syndromes.

[176]  P Gaucher,et al.  Patient-to-patient transmission of hepatitis C virus during colonoscopy. , 1997, The New England journal of medicine.

[177]  D. Desmond,et al.  Evaluation of needle and syringe combinations. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[178]  J. Patz,et al.  Occupational health in surgery: risks extend beyond the operating room. , 1995, The Australian and New Zealand journal of surgery.

[179]  E. Buning,et al.  PREVENTING AIDS IN DRUG ADDICTS IN AMSTERDAM , 1986, The Lancet.

[180]  J. Pawlotsky.  Treatment of chronic hepatitis C: current and future. , 2013, Current topics in microbiology and immunology.

[181]  D. Rein,et al.  Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. , 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[182]  Crime.,et al.  WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users.. , 2009 .

[183]  J. Kaldor,et al.  Hepatitis C Virus Acquisition among Injecting Drug Users: A Cohort Analysis of a National Repeated Cross-sectional Survey of Needle and Syringe Program Attendees in Australia, 1995–2004 , 2008, Journal of Urban Health.

[184]  C. B. Hare,et al.  Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. , 2006, Journal of acquired immune deficiency syndromes.

[185]  J. Duchin,et al.  Sharing of drug preparation equipment as a risk factor for hepatitis C. , 2001, American journal of public health.

[186]  R. Coutinho,et al.  Preventing AIDS in drug addicts in Amsterdam [letter] , 1986 .

[187]  S. Ciesek,et al.  Transmission of Hepatitis C Virus among People Who Inject Drugs: Viral Stability and Association with Drug Preparation Equipment , 2022 .